Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline PLC

www.gsk.com

Latest From GlaxoSmithKline PLC

DOJ's Investigation Of Reckitt's Suboxone Promotions Marks The Return Of The Big Settlement

$1.4b payment to settle investigation of marketing of opioid addition treatment is biggest for a pharma in several years.

Advertising, Marketing & Sales Legal Issues

FTC's First Product Hopping Complaint Targets Safety Claims For Suboxone Film Formulation

Commission files complaint as it reaches $50m settlement with Reckitt Benckiser.

Legal Issues Enforcement

Final ICH Q12 Post-Approval Changes Guideline Expected In November

A final revision of the ICH Q12 lifecycle management guideline is expected to overcome a conflict with EU variations legislation and offer more clarity on what is, and what is not, an established condition subject to post-approval change reporting requirements.

Manufacturing Quality

GSK Q2 Preview: Focus On PARP And HIV Pill

Analysts are waiting to see how the drugs giant intends to drive growth for new products, with a particular interest in the prospects for the PARP inhibitor Zejula and the single-pill, two-drug HIV therapy Dovato.

Sales & Earnings Cancer
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register